cMAP™ is a patented software which has been designed to be compatible with any Positive Airway Pressure (PAP) machine, including CPAPs

Predict and prevent to improve adherance

Our groundbreaking AI algorithms have been designed to deliver lower, more comfortable air pressures. This leads to an improvement in comfort and adherence on conventional CPAP machines. Building on cMAP™’s proprietary technology, we are also creating the groundwork to build the next generation of battery-enabled, wearable CPAPs.


Tested in clinical studies

cMAP™ is being developed based on tens of thousands of apneas collected from in-home patient’s CPAP machines. cMAP™ has been validated in a first-in-human trial on current CPAPs in a double-blinded sleep lab study at the QEII hospital in Halifax, Canada.


In a clinical trial, cMAP™ proved to:

Predict respiratory failure in advance of an apnea occurring
Predict the type of upcoming apnea (OSA, CSA and hypopnea)
Result in a statistically significant drop in AHI
Lower respiratory effort-related arousals (RERAs)
Lower a patient’s Non-REM heart rate

Clinical validation:

Q4 2019 – Q3 2020
Observational Study
Data collection from CPAP users:
  • Study completed on 70,000 apneas from CPAP users
  • High accuracies reached preceding apneas
Q4 2021 – Q4 2022
Interventional Study
Deploying cMAP™ on real patients:
  • Integration with commercial CPAPs
  • #NCT04873024
  • 22 patient – nights
  • 35% Reduction of AHI
Q4 2023-2024
Adherence and Comfort Studies

Improved comfort leads to
improved adherence

Aligned incentives that
benefit all stakeholders

  • Revenue increase for manufacturers due to greater initial acceptance and continued patient use of CPAP machines
  • Every 5 years new device (device sales)
  • Increase consumable resupply purchases as more patients use their CPAP machines and for more of the machine’s useful life
  • Potential for Reduced COGS and greater margins because cMAP™ technology leads to smaller more compact devices without loss of efficacy.
  • Increased revenue for Durable Medical Equipment suppliers (DMEs) due to increased sales of machines and consumable resupply
  • Reduction in labor cost for DMEs because more comfortable use leads to less required patient support
  • QoL increases
  • Reduction of co-morbid conditions associated with untreated OSA (heart disease1, diabetes2, stoke3,4 etc.)
  • 12+ months are lifetime users

Want to learn more?

Learn about the benefits that increased adherence can have for your company

Contact Us